COMPANY
Isomorphic Labs
Overview
Isomorphic Labs is the Alphabet-owned AI-for-drug-discovery company spun out of DeepMind in 2021, building on the AlphaFold protein-structure-prediction lineage to push computational drug design. As of May 2026, Isomorphic operates the Drug Design Engine (shipped February 2026), holds an expanded partnership with Eli Lilly, and recently closed a $2.1B funding round — making it one of the load-bearing data points that the dedicated AI-for-science track inside Alphabet is scaling on a separate budget from Google’s general-purpose AI work.
Timeline
- 2026-05-25-AI-Digest — Isomorphic Labs surfaces as load-bearing counter-evidence to the “AI-for-science is being absorbed into general agentic coding stacks” framing of John Jumper’s pivot to general coding at Google: Isomorphic shipped its Drug Design Engine in February, expanded the Eli Lilly partnership earlier this month, and raised a $2.1B round. Combined with DeepMind‘s Co-Scientist launch and the DOE Genesis program, the cleaner read of Jumper’s reallocation is bifurcation — Google moved one Nobel-laureate-shaped chunk of attention toward shoring up its developer-tool position against Anthropic and OpenAI, while the dedicated science-AI track inside Alphabet (Isomorphic + DeepMind) continues to scale on a separate budget.
Key Developments
-
Drug Design Engine (February 2026): First-product release for the company, productising AlphaFold-lineage protein-structure prediction into a drug-design workflow. The shipped-product milestone is the load-bearing piece — Isomorphic moved from research lab to product company.
-
Eli Lilly Partnership Expansion (May 2026): An expanded partnership with one of the largest pharmaceutical companies in the world is the strongest single revenue-side validation of the Drug Design Engine commercial thesis.
-
$2.1B Funding Round (May 2026): One of the largest single rounds for an AI-for-science company. Combined with Alphabet ownership, the capital base is the structural piece that makes the bifurcation read of Jumper’s Google pivot credible — the dedicated science-AI track is funded to keep scaling independently.